Form 4: Lantheus Holdings Director Mary Anne Heino Reports Stock Transactions

Mary Anne Heino, a director at Lantheus Holdings, reported the acquisition and disposal of common stock on March 4, 2024, according to a Form 4 filing with the SEC.

Summary

• On March 4, 2024, Mary Anne Heino, a director at Lantheus Holdings, Inc., reported transactions involving the company's common stock.
• Heino acquired 81,169 shares of common stock upon the vesting of relative Total Shareholder Return PSUs at a price of $0.00.
• Heino also sold 34,512 shares at a weighted average price of $64.8108, 59,251 shares at a weighted average price of $65.5941, and 100 shares at $66.225.
• Following these transactions, Heino directly owns 251,643 shares and indirectly owns 378,980 shares through a Grantor Retained Annuity Trust.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 9, 2023.
• The vesting of the PSUs equaled 200% of the target number of shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The PSU vesting at 200% is a positive indicator, but the sale of shares, even under a 10b5-1 plan, introduces a degree of caution.

Positives

• The vesting of PSUs at 200% of the target number of shares suggests strong performance relative to the set goals.

Negatives

• The sale of shares by a director could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• While the sales were conducted under a 10b5-1 trading plan, significant insider selling could create negative market sentiment.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical and biotechnology industries, as it can provide insights into management's perspective on the company's future prospects. Rule 10b5-1 plans are commonly used to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• It is common for executives and directors in publicly traded companies, including those in the pharmaceutical sector like Lantheus Holdings, to utilize 10b5-1 trading plans to manage their stock holdings.
• Companies like GE Healthcare, Siemens Healthineers, and Philips also have executives who use similar plans.
• The vesting of PSUs at 200% suggests that Lantheus Holdings has exceeded its performance targets, which is a positive sign compared to industry peers where PSU vesting may be at lower percentages.

Stakeholder Impact

• The vesting of PSUs and subsequent sale of shares could have a minor impact on shareholder value, depending on market perception.
• The vesting of PSUs is a positive sign for employees, as it indicates that performance goals were exceeded.

Key Dates